Dainippon Sumitomo raises guidance on US Latuda growth
This article was originally published in Scrip
Dainippon Sumitomo Pharma (DSP) has raised its financial guidance for the fiscal year ending 31 March, mainly on stronger than expected US sales of its atypical antipsychotic Latuda (lurasidone).
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.